Quarterly Results
NARI Earnings Forecast
Looking ahead, NARI remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2024/Q4 project quarter revenue of 160.70M and an EPS of 0.01.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2024 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming Q4 2024, revenue estimates have been adjusted No Change by 0% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in NARI long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how NARI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NARI sees a +1.83% change in stock price 10 days leading up to the earnings, and a +1.86% change 10 days following the report. On the earnings day itself, the stock moves by +0.17%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2024, the stock changed 15.55% on the day following the earnings release and then changed by 25.35% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of NARI's latest earnings report for FY2024Q3?
NARI reported its FY2024Q3 earnings on 2024-10-28, showcasing a revenue of 153.39M against an estimate of 150.67M, resulting in a 1.8% surprise. The EPS was -0.13, surpassing the expected -0.12 by -8.33% . The stock experienced a 15.55% price change on the earnings day and a 14.97% change over the next five days, reflecting market reactions to the results.
How did NARI's stock price react after the FY2024Q3 earnings release?
Following NARI's FY2024Q3 earnings announcement on 2024-10-28, the stock price moved by 15.55% on the day of the release. Over the subsequent five days, it saw a 14.97% change. Historically, NARI's stock price tends to shift by an average of +1.83% in the 10 days leading up to earnings and +1.86% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for NARI for 2024/Q4?
For 2024/Q4, analysts estimate NARI’s annual revenue to reach 160.70M, while the EPS is projected at 0.01. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.
How does NARI's stock price correlate with earnings forecast revisions?
The correlation between NARI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2024 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from NARI's next earnings report?
Based on historical trends, NARI's stock price typically moves by +1.83% in the 10 days before its earnings and +1.86% in the 10 days after. For the upcoming 2024/Q4 earnings, analysts expect an EPS of 0.01 and revenue of 160.70M.
What is the sentiment in Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Summary?
The earnings call presents mixed signals. Financial performance shows strong revenue growth but also increased operating losses, which is concerning. The Q&A section reveals stable market health and growth potential, but management's vague responses on certain topics may raise investor concerns. The lack of a shareholder return plan and declining gross margins also contribute to a neutral outlook. However, the raised annual revenue guidance and robust growth in emerging therapies offer positive aspects, balancing the negative elements. Given the company's market cap, the stock price is likely to remain stable over the next two weeks.
